1. Home
  2. GLSI vs VSTA Comparison

GLSI vs VSTA Comparison

Compare GLSI & VSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLSI
  • VSTA
  • Stock Information
  • Founded
  • GLSI 2006
  • VSTA 1966
  • Country
  • GLSI United States
  • VSTA Brazil
  • Employees
  • GLSI N/A
  • VSTA N/A
  • Industry
  • GLSI Biotechnology: Pharmaceutical Preparations
  • VSTA Other Consumer Services
  • Sector
  • GLSI Health Care
  • VSTA Real Estate
  • Exchange
  • GLSI Nasdaq
  • VSTA Nasdaq
  • Market Cap
  • GLSI 159.8M
  • VSTA 187.6M
  • IPO Year
  • GLSI 2020
  • VSTA 2020
  • Fundamental
  • Price
  • GLSI $11.95
  • VSTA $2.75
  • Analyst Decision
  • GLSI Strong Buy
  • VSTA Sell
  • Analyst Count
  • GLSI 1
  • VSTA 2
  • Target Price
  • GLSI $38.00
  • VSTA $3.00
  • AVG Volume (30 Days)
  • GLSI 24.6K
  • VSTA 17.0K
  • Earning Date
  • GLSI 04-14-2025
  • VSTA 03-19-2025
  • Dividend Yield
  • GLSI N/A
  • VSTA N/A
  • EPS Growth
  • GLSI N/A
  • VSTA N/A
  • EPS
  • GLSI N/A
  • VSTA N/A
  • Revenue
  • GLSI N/A
  • VSTA $280,865,717.00
  • Revenue This Year
  • GLSI N/A
  • VSTA $13.03
  • Revenue Next Year
  • GLSI N/A
  • VSTA $9.88
  • P/E Ratio
  • GLSI N/A
  • VSTA N/A
  • Revenue Growth
  • GLSI N/A
  • VSTA 6.41
  • 52 Week Low
  • GLSI $10.52
  • VSTA $1.60
  • 52 Week High
  • GLSI $21.44
  • VSTA $4.10
  • Technical
  • Relative Strength Index (RSI)
  • GLSI 40.69
  • VSTA 53.88
  • Support Level
  • GLSI $11.87
  • VSTA $2.55
  • Resistance Level
  • GLSI $12.95
  • VSTA $2.89
  • Average True Range (ATR)
  • GLSI 0.59
  • VSTA 0.16
  • MACD
  • GLSI -0.05
  • VSTA -0.02
  • Stochastic Oscillator
  • GLSI 25.19
  • VSTA 57.31

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.

About VSTA Vasta Platform Limited

Vasta Platform Ltd operates as an education company in Brazil, engaged in providing end-to-end educational and digital solutions that cater to all needs of private schools operating in the K-12 educational segment. Its business segments are Content and EdTech Platform, and Digital Platform. The Content and EdTech platform derives its results from educational content solutions through digital and printed content, including textbooks, learning systems and other complementary educational services. The Digital Platform enables private schools to aggregate multiple learning strategies and helps them to focus on education through the Business' physical and digital e-commerce platform and other digital services.

Share on Social Networks: